British Medical Association ‘in favour’ of reclassifying Lovima and Hana progestogen-only contraceptives from POM to P medicines

Responding to the MHRA consultation on the switch, the BMA has backed the proposals, but said it would be “pertinent” to address some issues relating to safeguarding and the potential for a reduction in the use of long-acting reversible contraceptives.

Source:

Pharmaceutical Journal